GLPwatch
Wegovy vs Xultophy
Drug comparison
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) and Xultophy (liraglutide) are both injectable medications made by Novo Nordisk, but they treat different conditions: Wegovy is approved for obesity and reducing cardiovascular risk, while Xultophy is for type 2 diabetes. The main difference is their active ingredients—Wegovy uses semaglutide, and Xultophy uses liraglutide—though both are given as shots under the skin.
AI summary of the sources below.
| Wegovy | Xultophy | |
|---|---|---|
| Active ingredient | semaglutide | liraglutide |
| Manufacturer | novo-nordisk | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | obesity, cardiovascular risk reduction | type 2 diabetes |
| Label updated | 2026-05-05 | 2025-10-14 |